Doctors should use different therapies when tr... - CLL Support

CLL Support

22,366 members38,466 posts

Doctors should use different therapies when treating older and younger CLL patients

Cllcanada profile image
CllcanadaTop Poster CURE Hero
0 Replies

From Science Daily...

'Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center.

Key conclusions include:

Fludarabine versus chlorambucil: Fludarabine improved progression-free survival and overall survival among patients younger than age 70 but chlorambucil tended to produce higher overall survival in patients older than 70.

Rituximab combined with fludarabine, versus fludarabine alone, improves progression-free and overall survival in both younger and older patients.

Alemtuzumab, aka Campath, ,consolidation therapy after chemotherapy or chemoimmunotherapy does not improve progression-free or overall survival in either younger or older patients.'

Article...

sciencedaily.com/releases/2...

Source

jco.ascopubs.org/content/ea...

CLL CANADA cllcanada.ca

____________________

~chris

CLL CANADA: cllcanada.ca

CLL Guidelines:

bloodjournal.hematologylibr...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...

You may also like...

An Early Look at When CAR-T Therapy Fails Patients With CLL

rate — 82% of patients with CLL had an overall response with the anti-CD19 CAR-T therapy...

quinine to treat cramps and cll patients.

husband has been given two different opinions, one the cll consultant saying quinine should be...

Dr Jeff Sharman - How I Treat My Patients With CLL Who Are Fit or Otherwise Healthy

20% of all treated patients; when treated with FCR the progression-free survival rate in this group...

Late breaking CLL abstract at ASH 2018 (FCR vs IR for untreated younger patients)

ibrutinib-based therapy as the most efficacious first-line therapy for patients with CLL.

Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL

significantly lower median overall survival (OS) than fit patients or patients that develop...